Canoe Health investor’s one-year losses jump 78%, stock up US$42m in a week

Canoe Health, Inc. ,NYSE:CANO) shareholders should be pleased to see the stock price jump 10% in the last month. But that doesn’t change the fact that the returns over the last year have been heartening. Notably, the stock price dropped 78% during that time. So it’s not surprising to see a slight jump. What’s important is whether the company can convert it over the long term.

As Cano Health has whittled US$42m off its value over the last 7 days, let’s see if the longer term decline is driven by the economics of the business.

Check out our latest analysis for Canoe Health

Because Canoe Health has posted a loss over the past twelve months, we think the market is probably more focused on revenue and revenue growth, at least for now. Shareholders of unprofitable companies typically expect strong revenue growth. Few companies are willing to postpone profitability in order to grow revenue faster, but in that case decent top-line growth can be expected.

Cano Health increased its revenue by 85% over the previous year. This is a strong result that is better than most other loss-making companies. So the massive 78% share price crash makes us think that the company has somehow pissed off the market participants. Something strange is definitely affecting the stock price; We would venture that the company has destroyed value in some way. One thing is clear that the market is not yet assessing the revenue growth of the company. Of course, investors tend to overreact when stressed, so the selloff can be unduly severe.

The company’s revenue and earnings (over time) are shown in the image below (click to see exact numbers).

NYSE: CANO Earnings and Revenue Growth Jan 25 2023

We like that insiders have been buying shares over the past twelve months. Having said that, most people find earnings and revenue growth trends to be more meaningful guides to a business. That’s why we recommend checking it out free Reports showing consensus forecasts

a different perspective

We doubt that Canoe Health’s shareholders are happy with a loss of 78% in trailing twelve months. This is lower than the market, which declined by 7.9%. It’s disappointing, but it’s worth bearing in mind that market-wide sales wouldn’t have helped. Share price decline has continued, down 68% over the past three months, indicating a lack of investor enthusiasm. Basically, most investors should be wary of buying into an underperforming stock unless the business is clearly improving. I find it very interesting to look at share price over the long term as a proxy for business performance. But to really gain insight, we need to consider other information as well. Like risk, for example. every company has, and we’ve seen 3 warning signs for Canoe Health (1 of which should not be overlooked!) You should be aware of this.

If You Like Buying Stocks Along With Management, You May Like This free List of companies. (Hint: Insiders are buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

what are the risks and opportunities ear health,

Canoe Health, Inc. Provides primary care medical services to its members in the United States and Puerto Rico.

View full analysis

Award

  • is trading 76.6% below our estimate of its fair value

  • Earnings are projected to grow by 55.28% per annum

risk

  • Highly volatile share price in last 3 months

  • Shareholders have been diluted over the past year

  • Has a cash runway of less than 1 year

See all Risks and Rewards

This article from Simply Wall St is general in nature. We only provide commentary based on historical data and analyst forecasts using an unbiased methodology and our articles are not intended to provide financial advice. It is not a recommendation to buy or sell any stock, and does not take into account your objectives, or your financial situation. We aim to bring you long term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall Street has no position in any of the stocks mentioned.

Leave a Comment